no argument here the relative benefit per buck in HCV is striking compared to costs of many other drugs (even other breakthrough drugs) i don't think we're going to see anything like this any time soon in other areas of medicine however. Here you had a very unique setup with HCV regimens with virtually identical cure rates and one company realizing it may have to leverage price due to a minor disadvantage like pill burden
Market Data 
Markets 
AI
